A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator

PHASE1CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

September 22, 2020

Primary Completion Date

April 6, 2022

Study Completion Date

April 6, 2022

Conditions
Healthy VolunteersPneumococcal Disease
Interventions
BIOLOGICAL

ASP3772

Intramuscular (IM) injection

BIOLOGICAL

PCV13

Intramuscular injection

Trial Locations (17)

19401

Pediatrics Medical Associates, East Norriton

28625

PMG Research, Statesville

29414

Coastal Pediatric Associates, Charleston

33435

Gentle Medicine Associates, Boynton Beach

40004

Kentucky Pediatric/Adult Research, Bardstown

70806

Meridian Clinical Research, Baton Rouge

72022

Dermatology Trial Associates, Bryant

72401

The Childrens Clinic, Jonesboro

74127

Oklahoma State University Center for Health Sciences, Tulsa

77090

Houston Clinical Research Associates, Houston

77555

University of Texas Medical Branch, Galveston

84041

Tanner Clinic, Layton

84604

Pediatric Care, Provo

91790

Ctr Clin Trials San Gabriel, West Covina

92804

Emmaus Research Center, Inc, Anaheim

93637

Madera Family Medical Group, Madera

99202

MultiCare Institute, Spokane

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Affinivax, Inc.

INDUSTRY

NCT04525599 - A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator | Biotech Hunter | Biotech Hunter